Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study

BACKGROUND: Fruquintinib is an oral vascular endothelial growth factor receptor inhibitor. Previous gefitinib studies with anti-angiogenics show promising efficacy. This phase II trial assessed efficacy and safety of fruquintinib in combination with gefitinib, in patients with advanced non-small cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Zhou, Jian-Ying, Niu, Xiao-Min, Zhou, Jian-Ya, Jian, Hong, Yin, Hong-Yan, Guan, Sha, Wang, Lin-Fang, Li, Ke, He, James, Su, Wei-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947379/
https://www.ncbi.nlm.nih.gov/pubmed/33718026
http://dx.doi.org/10.21037/tlcr-20-1028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947379/
https://www.ncbi.nlm.nih.gov/pubmed/33718026
http://dx.doi.org/10.21037/tlcr-20-1028

Ejemplares similares